Data Matrix, LTD   Report issue

For profit Phase 2
Founded: Saint Petersburg Russian Federation (2014)

Organization Overview

First Clinical Trial
2016
NCT03546621
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Data Matrix | Data Matrix Solutions

Active Ingredients

Drugs in Phase 2 Trials (5)

bulevirtide (1 trial)

diclofenac (voltaren) (1 trial)

Goflikicept (1 trial)

pf-114 (1 trial)

tenofovir (viread) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis, Gouty (Phase 2)

Gout (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis, Chronic (Phase 2)

Hepatitis D (Phase 2)

Hepatitis D, Chronic (Phase 2)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 5